Omega-3 Prescription Drugs Market Market Analysis

Drug Type (Vascepa, Lovaza)

The vascepa segment is anticipated to hold a revenue share of around 47.7% in the omega-3 prescription drugs market during the forecast period. Such a dominating position is mainly due to its already established preference to reduce cardiovascular risks among patients suffering from high levels of triglycerides. Vascepa is uniquely formulated based on highly purified EPA and has been approved by the FDA, extending its applicability in the prevention of heart disease. In August 2023, Amarin Corporation and Neopharm collaborated to make an exclusivity agreement for the commercialization of VAZKEPA in Israel, continuing to further strengthen the company's leading position in international markets. Such developments are anticipated to boost the segment’s growth over the forecast period.

Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

By 2037, retail pharmacy segment is expected to hold more than 52.3% omega-3 prescription drugs market share. This is due to the increasing convenience and accessibility of prescription drugs from retail settings. Preference for over-the-counter solutions among the patients is one of the major distribution dynamics that drives the omega-3 products. This is also being driven by the increasing adoption of e-prescriptions and telehealth services. In October 2022, the European Commission approved plant-based omega-3 products from DSM, enabling its wider dissemination across retail pharmacies within the EU. Such approvals are likely to drive the sales of omega-3 prescription drugs in retail pharmacies during the forecast period.

Our in-depth analysis of the omega-3 prescription drugs Market includes the following segments: